

ORIGINAL RESEARCH—ERECTILE DYSFUNCTION

Uric Acid Level and Erectile Dysfunction in Patients with Coronary Artery Disease

Yalcin Solak, MD,* Hakan Akilli, MD,[†] Mehmet Kayrak, MD,[†] Alpay Aribas, MD,[†] Abduzhappar Gaipov, MD,^{‡§} Suleyman Turk, MD,[§] Santos E. Perez-Pozo, MD,[¶] Adrian Covic, MD,^{**} Kim McFann, PhD,^{††} Richard J. Johnson, MD,^{††} and Mehmet Kanbay, MD^{††}

*Nephrology Unit, Department of Internal Medicine, Karaman State Hospital, Karaman, Turkey; [†]Department of Cardiology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey; [‡]Department of Extracorporeal Hemocorrection, National Scientific Medical Research Center, Astana, Kazakhstan; [§]Department of Nephrology, Necmettin Erbakan University, Meram School of Medicine, Konya, Turkey; [¶]Dialysis Department, Centro Nacional de Salud Renal—Essalud, Lima, Peru; ^{**}Nephrology Clinic, Dialysis and Renal Transplant Center, “C.I. PARHON” University Hospital, “Gr. T. Popa” University of Medicine and Pharmacy, Iasi, Romania; ^{††}Division of Renal Diseases and Hypertension, University of Colorado, Denver, CO, USA; ^{††}Department of Medicine, Division of Nephrology, Istanbul Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey

DOI: 10.1111/jsm.12332

ABSTRACT

Introduction. Erectile dysfunction (ED) is a frequent complaint of elderly subjects and is closely associated with endothelial dysfunction and cardiovascular disease (CVD). Uric acid is also associated with endothelial dysfunction, oxidative stress, and CVD, raising the hypothesis that an increased serum uric acid might predict ED in patients who are at risk for coronary artery disease (CAD).

Aim. This study aims to evaluate the association of serum uric acid levels with presence and severity of ED in patients presenting with chest pain of presumed cardiac origin.

Methods. This is a cross-sectional study of 312 adult male patients with suspected CAD who underwent exercise stress test (EST) for workup of chest pain and completed a sexual health inventory for men survey form to determine the presence and severity of ED. Routine serum biochemistry (and uric acid levels) were measured. Logistic regression analysis was used to assess risk factors for ED.

Main Outcome Measures. The short version of the International Index of Erectile Function questionnaire diagnosed ED (cutoff score ≤ 21). Serum uric acid levels were determined. Patients with chest pain of suspected cardiac origin underwent an EST.

Results. One hundred forty-nine of 312 (47.7%) male subjects had ED by survey criteria. Patients with ED were older and had more frequent CAD, hypertension, diabetes and impaired renal function, and also had significantly higher levels of uric acid, fibrinogen, glucose, C-reactive protein, triglycerides compared with patients without ED. Uric acid levels were associated with ED by univariate analysis (odds ratio = 1.36, $P = 0.002$); however, this association was not observed in multivariate analysis adjusted for estimated glomerular filtration rate.

Conclusion. Subjects presenting with chest pain of presumed cardiac origin are more likely to have ED if they have elevated uric acid levels. Solak Y, Akilli H, Kayrak M, Aribas A, Gaipov A, Turk S, Perez-Pozo SE, Covic A, McFann K, Johnson RJ, and Kanbay M. Uric Acid level and erectile dysfunction in patients with coronary artery disease. *J Sex Med* 2014;11:165–172.

Key Words. Uric Acid; Erectile Dysfunction; Coronary Artery Disease; Endothelial Dysfunction

Introduction

Erectile dysfunction (ED) is fairly common, especially among elderly men, and is associated with coronary artery disease (CAD) [1–4]. The association of ED has been attributed to the presence of common risk factors such as obesity, hypertension, diabetes, and smoking. Not surprisingly, prospective observational studies have reported that subjects with ED are at risk for future cardiovascular (CV) events [5]. A recent meta-analysis also reported that ED significantly increases the risk of cardiovascular disease (CVD), CAD, stroke, and all-cause mortality. Moreover, the increase was independent of conventional cardiovascular risk factors [6].

ED is strongly associated with the presence of small vessel disease and endothelial dysfunction [7,8]. Subjects with long-standing hypertension, who develop small vessel disease (arteriosclerosis), are also susceptible to developing ED independent of specific antihypertensive agents [9]. In this regard, uric acid becomes an interesting potential risk factor for ED, as it is strongly linked with endothelial dysfunction [10–12], microvascular disease [13], and hypertension [14,15]. Experimental studies show that uric acid can reduce endothelial nitric oxide bioavailability via multiple mechanisms, including scavenging by uric acid-induced oxidative stress, the stimulation of arginase, and direct scavenging [16–19]. Uric acid can also induce vascular smooth muscle cell proliferation *in vitro* and induce microvascular disease *in vivo*, and studies in humans have linked uric acid with microvascular disease [20–24]. An elevated uric acid is also emerging as an independent predictor of hypertension, and pilot clinical studies suggest lowering uric acid can improve endothelial function and lower blood pressure in hypertensive subjects [25–27]. Despite these associations, to date no studies have examined the relationship of uric acid levels to ED.

Uric acid has also been recognized as a novel risk factor for development of CAD, although meta-analyses are mixed on the independence of this relationship [28–30]. Recently we reported that ED is a risk factor for CV disease in subjects presenting with chest pain. Here we used the same cohort study to address a new question—could uric acid be a predictor for ED? We further hypothesized that increased serum uric acid levels may be one of the missing links between CAD and ED. With this background in mind, we evaluated the association of serum uric acid levels with pres-

ence and severity of ED in patients presenting with chest pain of presumed cardiac origin.

Materials and Methods

This was a cross-sectional study, and the participants were recruited from a prospectively maintained cohort. Previously we reported that reduced estimated glomerular filtration rate (eGFR), and presence and severity of ED were associated with severity of CAD in this cohort [31]. We included 312 consecutive adult male patients who for the first time presenting with chest pain to our cardiology outpatient clinic. Only married men with a permanent sexual partner were included. Exclusion criteria were as follows: previous evaluation for CAD by coronary angiography, history of established CAD (previous myocardial infarction, coronary artery bypass grafting surgery, heart failure or percutaneous coronary angioplasty), drug therapy for CAD, drug therapy for known ED, liver cirrhosis, gout, chronic obstructive pulmonary disease, depression, cancer and chronic renal replacement therapy. We also excluded subjects if they were taking allopurinol. After detailed medical history and thorough physical examination, patients with chest pain of suspected cardiac origin underwent an exercise stress test (EST). Patients who were deemed to have noncardiac chest pain or required no further testing were excluded from the study. Final participants were subjects who had chest pain of suspected cardiac origin as determined by the clinical exam and EST.

The study was approved by Local Ethics Committee, and all the participants signed written informed consent forms before recruitment. Patients were examined with good medical and laboratory practice according to the recommendations set forth by the Declaration of Helsinki on biomedical research involving human subjects.

Included patients were instructed to complete the sexual health inventory for men (SHIM) survey form. SHIM, also known as International Index of Erectile Function is an established, valid, and reliable questionnaire for determining the presence and severity of ED [32]. Patients with SHIM scores ≤ 21 were diagnosed with ED.

Based on the definitions of the Framingham Heart Study, patients who were smoking > 10 cigarettes/day were accepted as smokers, and patients who ceased smoking more than 2 years ago were accepted as nonsmokers. Hypertension and diabetes mellitus were described according to the Seventh Report of the Joint National Commit-

tee [33] and World Health Organization criteria [34]. Patients with total serum cholesterol values >200 mg/dL were defined as dyslipidemic.

All patients included in the study underwent EST with the multistage Bruce protocol. Whenever feasible, beta-blockers and calcium channel blockers were discontinued for 24–48 hours before the treadmill test. The criteria for ending the test involved an ST depression of 2 mm and an ST elevation of 1 mm compared with resting electrocardiogram, a decrease in systolic blood pressure (SBP) more than 10%, no increase in heart rate or development of bradycardia, a blood pressure reading greater than 250/130 mm Hg, presence of class 3–4 angina, significant arrhythmia, reaching target heart rate, and fatigue precluding further exercise. Patients with positive EST underwent conventional coronary angiography (CAG). Selective CAG was performed via Judkins technique through femoral artery route with multiprojection. All angiograms were evaluated by two blind observers who were unaware of the results of the EST. A 50% and more luminal diameter narrowing were accepted as a significant lesion via visual assessment in major epicardial coronary arteries or their major branches. All patients were compared and classified into four groups according to CAG results as follows: normal coronary artery, single-vessel CAD, two-vessel CAD, and three-vessel CAD.

Venous blood samples were collected from all participants to measure serum glucose, blood urea nitrogen, creatinine, sodium, potassium, uric acid, fibrinogen, high sensitive C-reactive protein (CRP), and lipid profile. Spot urine sample was collected to measure urinary albumin excretion. eGFR was calculated by using the Cockcroft-Gault equation [35].

Statistical Analyses

Wilcoxon Sign Rank test was used to compare continuous variables between those without ED vs. those who do have ED. Chi-squared test of independence or Fisher's exact was used to compare categorical variables between groups. Logistic regression was used to test the unadjusted relationship between uric acid and quartiles of uric acid on ED. Univariate logistic regression was used to test the relationship of several risk factors with ED. A series of multivariate logistic regression models were tested using variables selected from univariate analyses with either uric acid as a continuous variable or quartiles of uric acid. $P < 0.05$ was considered significant. All calcula-

tions were performed by using a standard statistical package (SAS 9.2, Cary, NC, USA).

Results

Three hundred twelve male subjects were included in the study: 149 with ED and 163 without ED. Subjects with ED were older and were more likely to have angiographically proven CAD, hypertension, diabetes, worse renal function, and a positive treadmill test (Table 1). In addition, those with ED had higher acetylsalicylic acid use and higher serum fibrinogen, glucose, CRP, triglycerides, and uric acid levels compared with patients without ED (Table 1). In unadjusted analysis, uric acid, as a continuous variable, was associated with ED for each 1 mg/dL increase in serum uric acid level (odds ratio [OR] = 1.361 [1.121–1.652], $P = 0.0019$). In unadjusted analysis, the 4th quartile of uric acid was associated with ED compared with the 1st quartile (OR = 2.638 [1.378–5.048], $P = 0.0034$). There was no association of the 2nd or 3rd quartiles of uric acid with ED.

Next we examined risk factors associated with ED in univariate logistic regression analysis. Known CV risk factors and diabetes were significantly associated with ED in univariate logistic regression (Table 2). To determine the independent contribution of uric acid to ED, we constructed a series of multiple regression models based on risk factors impacting ED. All of the parameters that significantly correlated with ED were introduced in standard multivariate regression analysis in a three-step procedure. In the first step, we evaluated the independent influence of uric acid and age on ED in our population. In this first step, uric acid (OR = 1.36; $P = 0.0029$) and age (OR = 1.08, $P < 0.0001$) were both statistically significant independent predictors that correlated with ED (Table 3). In the second step, we adjusted for age and presence of CAD. After these adjustments, serum uric acid (OR = 1.31, $P = 0.01$), age (OR = 1.08, $P < 0.0001$), and CAD (OR = 3.12, $P < 0.0001$) remained statistically significant predictors of the ED (Table 3). In the third step, we adjusted for age, eGFR, and the presence of CAD. After these adjustments, uric acid lost its significance (OR = 1.21, $P = 0.088$) (Table 3).

Multiple logistic regression was also performed, including the above-selected variables, as well as hypertension and diabetes. As expected, uric acid and quartiles of uric acid were not found to be independent risk factors for ED (Table 4).

Table 2 Univariate logistic regression of risk factor association with erectile dysfunction

	OR and 95% CI	P value
ACEi	1.869 (1.045–3.342)	0.0350
Age (years)	1.082 (1.049–1.115)	<0.0001
Beta blocker	1.788 (0.750–4.262)	0.1900
BMI	0.999 (0.928–1.075)	0.9747
Coronary artery disease	3.154 (1.926–5.166)	<0.0001
eGFR	0.960 (0.948–0.972)	<0.0001
Diabetes mellitus	2.788 (1.389–5.596)	0.0039
Diuretic	2.65 (1.21–5.801)	0.0148
Hypertension	1.897 (1.170–3.075)	0.0095
hsCRP	1.131 (1.049–1.219)	0.0013
Uric acid	1.361 (1.121–1.652)	0.0019
Smoking	1.088 (0.696–1.701)	0.7121
Total cholesterol	1.004 (0.998–1.009)	0.1642

ACEi = angiotensin converting enzyme inhibitor; eGFR = estimated glomerular filtration rate; hsCRP = high-sensitive C-reactive protein; BMI = body mass index

Additional Analyses

Serum uric acid had weak correlations with eGFR ($r = -0.19$, $P = 0.0009$), diastolic blood pressure ($r = 0.17$, $P = 0.0056$), SBP ($r = 0.15$, $P = 0.0129$), low density lipoproteins ($r = 0.13$, $P = 0.0254$), CRP ($r = 0.17$, $P = 0.0048$), cholesterol ($r = 0.20$, $P = 0.0006$), and triglycerides ($r = 0.22$, $P = 0.0001$). The 4th quartile of uric acid was associated with increased odds of CAD, OR = 2.30 (1.170–4.521), $P = 0.0158$. When ED was regressed on CAD and quartiles of uric acid, both CAD,

OR = 2.821 (1.691–4.704), $P < 0.0001$ and the 4th quartile of uric acid, OR = 2.287 (1.171–4.466), $P = 0.0154$, were associated with ED.

Discussion

Our primary finding is that an elevated serum uric acid level is associated with the presence of ED in subjects with suspected CAD. For each change in 1 mg/dL uric acid, there was a 31% increased risk for having ED. However, when this relation was adjusted for traditional cardiovascular risk factors, the relationship with serum uric acid level was no longer significant.

The importance of epidemiology in generating hypotheses is well established. Ideally, one tries to identify risk factors that are strongly associated with an outcome and which are independent of other risk factors when multivariate analyses are used. For example, coffee drinking may be related to CAD by univariate analysis, yet this association may be accounted for by the finding that coffee drinkers are also more commonly people who smoke tobacco. Hence, coffee drinking may not be independent of smoking as a risk factor for CAD, and coffee is not a true risk factor as it is the smoking that is truly responsible for the association. However, we might also do an analysis that

Table 1 Comparison of patients without ED vs. those with ED

	Patients without erectile dysfunction (N = 163)	Patients with erectile dysfunction (N = 149)	P value
Uric acid (mg/dL)	5.4 ± 1.2	5.8 ± 1.3	0.0046
Age (years)	53.8 ± 7.5	58.8 ± 8.5	<0.0001
Coronary artery disease (n, %)	35 (21.5%)	69 (46.3%)	<0.0001
Diabetes mellitus (n, %)	13 (8.0%)	29 (19.5%)	0.0030
Hypertension (n, %)	41 (25.2%)	58 (38.9%)	0.0089
Smoking (n, %)	71 (43.6%)	68 (45.6%)	0.7120
eGFR	113.4 ± 30.8	93.4 ± 20.9	<0.0001
BMI (kg/m ²)	27.7 ± 3.0	27.7 ± 3.1	0.8638
Positive treadmill test (n, %)	53 (32.5%)	83 (55.7%)	<0.0001
HsCRP	3.8 ± 3.1	5.24 ± 3.83	0.0005
Systolic BP (mm Hg)	129.9 ± 20.7	133.9 ± 19.1	0.0498
Diastolic BP (mm Hg)	79.5 ± 14.3	82.0 ± 14.5	0.1393
Total cholesterol (mg/dL)	191.8 ± 38.4	198.5 ± 46.5	0.2006
LDL cholesterol (mg/dL)	118.6 ± 31.5	118.3 ± 36.3	0.8850
Triglycerides (mg/dL)	162.3 ± 100.5	211.0 ± 159.9	0.0075
HDL cholesterol (mg/dL)	40.2 ± 7.6	39.8 ± 8.3	0.4651
SHIM score	23.0 ± 0.98	16.2 ± 3.54	<0.0001
Medications			
ACEi use (n, %)	23 (14.1%)	35 (23.5%)	0.0334
ASA use (n, %)	0.20 ± 0.40	0.34 ± 0.47	0.0053
Beta blocker (n, %)	9 (5.52%)	14 (9.46%)	0.1851
Diuretic (n, %)	10 (6.1%)	22 (14.8%)	0.0121
Insulin user (n, %)	0 (0%)	6 (4.1%)	0.0110
Oral antidiabetic meds use (n, %)	11 (6.75%)	18 (12.1%)	0.1052
Statin (n, %)	17 (10.4%)	17 (11.4%)	0.7814

Table 3 Erectile dysfunction and uric acid as a continuous variable

	OR and 95% CI	P value
Unadjusted		
Uric acid	1.361 (1.121–1.652)	0.0019
Adjusted for age		
Age	1.081 (1.048–1.116)	<0.0001
Uric acid	1.364 (1.112–1.672)	0.0029
Adjusted for age + coronary artery disease		
Age	1.086 (1.051–1.122)	<0.0001
Coronary artery disease	3.128 (1.819–5.380)	<0.0001
Uric acid	1.311 (1.060–1.620)	0.0123
Adjusted for age + coronary artery disease + eGFR		
Age	1.048 (1.009–1.089)	0.0158
Coronary artery disease	2.389 (1.347–4.236)	0.0029
eGFR	0.974 (0.960–0.989)	0.0006
Uric acid	1.210 (0.972–1.506)	0.0888

finds that smoking is not independent of hypertension as a risk factor for stroke and we might wrongly conclude that smoking is not a true risk factor, when in fact smoking may cause CAD by causing hypertension. Thus, understanding how a risk factor works may help one to understand the potential assumptions associated with assuming a risk factor is causal [36]. This is particularly important for uric acid, as it is increasingly apparent that it may have multiple biological effects that could have contributory roles in many risk factors for CVD [37,38].

Recent studies have shown that soluble uric acid can have marked effects on the microvasculature [39]. Uric acid, while an antioxidant in the extracellular environment [40], causes oxidative stress when it elevated inside the cell, including in vascular smooth muscle cells and vascular endothelial cells [23,41]. The mechanism may be via the stimulation of nicotinamide adenine dinucleotide phosphate-oxidase [42]. In addition, uric acid potently reduces nitric oxide in endothelial cells and vascular smooth muscle cells, via multiple mechanisms [43]. Hyperuricemic rats show evidence for endothelial dysfunction that is reversed by normalizing the serum uric acid [44]. In addition, hyperuricemia is strongly associated with endothelial dysfunction in humans, including in asymptomatic hyperuricemia [11]. We and others have shown that lowering serum uric acid with xanthine oxidase inhibitors can improve endothelial dysfunction [45–48]. Whether this is due to specific blockade of xanthine oxidase or the lowering of intracellular uric acid in vascular cells remains debated. Uric acid can also induce inflammation and can increase CRP and chemokines via the activation of Mitogen-activated protein kinases and nuclear factor kappa-light-

chain-enhancer of activated B cells [49,50]. Lowering uric acid has been reported to improve CRP levels in both normal subjects and subjects with CKD [47,51]. Finally, uric acid can stimulate vascular smooth muscle cell proliferation in vitro and induced renal microvascular disease in vivo [23,52]. We have also linked serum uric acid with microvascular disease in the heart of patients undergoing myocardial infarction [52].

There are multiple factors involved in the pathogenesis of ED, including endothelial dysfunction, microvascular disease, alterations in testosterone levels, and psychological factors. The observation that uric acid may have a role in driving endothelial dysfunction and microvascular disease provides a potential causal link between uric acid and ED [25,52]. For example, thiazide diuretics are known to be one cause of ED and may cause ED due to their ability of causing endothelial dysfunction. In our study, diuretic use was more common in subjects with ED (15% vs. 6%, $P < 0.01$, Table 1). Interestingly, thiazide use also raises uric acid levels, and in animals, the thiazide-induced endothelial dysfunction can be reversed by lowering uric acid levels [53]. Thus, these data suggest the complex interplay of CV risk factors and uric acid in the potential etiology of ED. To truly determine if uric acid may have a role in ED, a clinical trial randomizing subjects with ED to uric acid lowering therapy might be useful. The consistent observation that lowering uric acid with allopurinol can improve endothelial dysfunction provides a further argument for performing such a study [54].

The observation that uric acid can induce endothelial dysfunction, oxidative stress, inflammation, and microvascular disease could provide a link between uric acid and CV disease and ED, as well as other risk factors for CAD. For example, there is now strong evidence that uric acid can independently predict the development of hypertension and insulin resistance, as reflected by recent

Table 4 Multiple logistic regression with quartiles of uric acid

Variables	OR (95% CI)	P value
Age	1.061 (1.014–1.109)	0.0104
Hypertension	1.264 (0.676–2.364)	0.4631
Diabetes mellitus	2.176 (0.953–4.966)	0.0648
Coronary artery disease	2.771 (1.498–5.126)	0.0012
eGFR	0.970 (0.955–0.986)	0.0003
Triglycerides	1.006 (1.003–1.009)	<0.0001
Quartile 2	1.347 (0.652–2.782)	0.4211
Quartile 3	0.899 (0.403–2.007)	0.7958
Quartile 4	1.334 (0.613–2.899)	0.4675

meta-analyses [25,53]. Raising uric acid in rats causes hypertension by causing oxidative stress, endothelial dysfunction, and microvascular disease [19,54,55]. Uric acid has also been found to have a causal role in both dietary and nondietary insulin resistance in laboratory animals, again through mechanisms involving oxidative stress and endothelial dysfunction [56–58]. Multiple studies also show that uric acid independently predicts the development of kidney disease and may accelerate its production by causing endothelial dysfunction [59,60]. Indeed, pilot studies suggest that lowering uric acid may have benefits on blood pressure [26,47,61], insulin resistance [62], and chronic kidney disease [51,63] in humans. Therefore, while our inability to show uric acid as an independent risk factor could be interpreted to mean that uric acid is not a true risk factor, the data are also compatible with the hypothesis that uric acid may have a contributory role to both ED as well as hypertension, insulin resistance, and renal function due to its central role in causing endothelial dysfunction, oxidative stress, and inflammation.

In conclusion, ED is recognized as a risk factor for CAD. In this study, we show that subjects presenting with chest pain of presumed cardiac origin are more likely to have ED if they have elevated uric acid levels. As lowering uric acid can reverse intracellular oxidative stress, inflammation, and endothelial dysfunction in animal models, we might suggest that studies should also be performed to determine the potential benefit of lowering uric acid in subjects with ED, in the presence or absence of CAD.

Acknowledgments

Dr. A.G. received grant support from the ERA-EDTA fellowship program. No sources of funding were used to conduct this study or prepare this manuscript. Dr. Kim McFann is supported in part by NIH/NCRR Colorado CTSI Grant Number UL1 RR025780.

Corresponding Author: Mehmet Kanbay, MD, Sağlık Bakanlığı İstanbul Medeniyet Üniversitesi Goztepe Eğitim ve Arastırma Hastanesi, Nefroloji Bilim Dalı, Kadıköy, İstanbul 034, Turkey. Tel: +902163234545; Fax: +902163234546; E-mail: drkanbay@yahoo.com

Conflict of Interest: Dr. R.J. Johnson is listed as an inventor on a patent for allopurinol to treat essential hypertension and is also an inventor on patent applications related to lowering uric acid in the prevention or treatment of hypertension, insulin resistance, and diabetic nephropathy. He has also served as a consultant for Novartis, Ardea, Danone, and Astellas and is on the Scientific Board of Amway. All other authors declared

no competing interests, and all authors had access to the data and played a role in writing this manuscript.

Statement of Authorship

Category 1

(a) Conception and Design

Mehmet Kayrak; Mehmet Kanbay; Suleyman Turk

(b) Acquisition of Data

Alpay Aribas; Hakan Akilli

(c) Analysis and Interpretation of Data

Kim McFann; Abdulhappar Gaipov; Yalcin Solak

Category 2

(a) Drafting the Article

Yalcin Solak; Mehmet Kanbay

(b) Revising It for Intellectual Content

Santos E. Perez-Pozo; Adrian Covic

Category 3

(a) Final Approval of the Completed Article

Richard J. Johnson

References

- 1 Salem S, Abdi S, Mehra S, Saboury B, Saraji A, Shokohideh V, Pourmand G. Erectile dysfunction severity as a risk predictor for coronary artery disease. *J Sex Med* 2009;6:3425–32.
- 2 Hall SA, Shackelton R, Rosen RC, Araujo AB. Sexual activity, erectile dysfunction, and incident cardiovascular events. *Am J Cardiol* 2010;105:192–7.
- 3 Frantzen J, Speel TG, Kiemeny LA, Meuleman EJ. Cardiovascular risk among men seeking help for erectile dysfunction. *Ann Epidemiol* 2006;16:85–90.
- 4 Kumar J, Bhatia T, Kapoor A, et al. Erectile dysfunction precedes and is associated with severity of coronary artery disease among Asian Indians. *J Sex Med* 2013;10:1372–9.
- 5 Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S, ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. *Circulation* 2010;121:1439–46.
- 6 Dong JY, Zhang YH, Qin LQ. Erectile dysfunction and risk of cardiovascular disease: Meta-analysis of prospective cohort studies. *J Am Coll Cardiol* 2011;58:1378–85.
- 7 Chai SJ, Barrett-Connor E, Gamst A. Small-vessel lower extremity arterial disease and erectile dysfunction: The Rancho Bernardo study. *Atherosclerosis* 2009;203:620–5.
- 8 Lojanapiwat B, Weerusawin T, Kuanprasert S. Erectile dysfunction as a sentinel marker of endothelial dysfunction disease. *Singapore Med J* 2009;50:698–701.
- 9 Prisant LM, Loebl DH Jr, Waller JL. Arterial elasticity and erectile dysfunction in hypertensive men. *J Clin Hypertens (Greenwich)* 2006;8:768–74.

- 10 Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F. Uric acid and endothelial dysfunction in essential hypertension. *J Am Soc Nephrol* 2006;17:1466–71.
- 11 Erdogan D, Gullu H, Caliskan M, et al. Relationship of serum uric acid to measures of endothelial function and atherosclerosis in healthy adults. *Int J Clin Pract* 2005;59:1276–82.
- 12 Kanbay M, Yilmaz MI, Sonmez A, et al. Serum uric acid level and endothelial dysfunction in patients with nondiabetic chronic kidney disease. *Am J Nephrol* 2011;33:298–304.
- 13 Johnson RJ, Segal MS, Srinivas T, et al. Essential hypertension, progressive renal disease, and uric acid: A pathogenetic link? *J Am Soc Nephrol* 2005;16:1909–19.
- 14 Feig DI, Johnson RJ. Hyperuricemia in childhood primary hypertension. *Hypertension* 2003;42:247–52.
- 15 Cannon PJ, Stason WB, Demartini FE, Sommers SC, Laragh JH. Hyperuricemia in primary and renal hypertension. *N Engl J Med* 1966;275:457–64.
- 16 Gersch C, Palii SP, Kim KM, Angerhofer A, Johnson RJ, Henderson GN. Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids 2008;27:967–78.
- 17 Zharikov S, Krotova K, Hu H, et al. Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells. *Am J Physiol Cell Physiol* 2008;295:C1183–90.
- 18 Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: Implication on cell proliferation and nitric oxide production of human vascular cells. *J Am Soc Nephrol* 2005;16:3553–62.
- 19 Sanchez-Lozada LG, Soto V, Tapia E, et al. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. *Am J Physiol Renal Physiol* 2008;295:F1134–41.
- 20 Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriopathy in rats by a blood pressure-independent mechanism. *Am J Physiol Renal Physiol* 2002;282:F991–7.
- 21 Kang DH, Han L, Ouyang X, et al. Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter. *Am J Nephrol* 2005;25:425–33.
- 22 Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. *J Biol Chem* 1991;266:8604–8.
- 23 Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. *J Hypertens* 2008;26:269–75.
- 24 Myllymaki J, Honkanen T, Syrjanen J, et al. Uric acid correlates with the severity of histopathological parameters in IgA nephropathy. *Nephrol Dial Transplant* 2005;20:89–95.
- 25 Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: A systematic review and meta-analysis. *Arthritis Care Res (Hoboken)* 2011;63:102–10.
- 26 Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on the blood pressure of adolescents with newly diagnosed essential hypertension. *JAMA* 2008;300:922–30.
- 27 Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. *Hypertension* 2005;45:28–33.
- 28 Kanbay M, Ikizsek M, Solak Y, et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. *Am J Nephrol* 2011;33:325–31.
- 29 Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. *Arthritis Care Res (Hoboken)* 2010;62:170–80.
- 30 Wheeler JG, Juzwishin KD, Eiriksdottir G, Gudnason V, Danesh J. Serum uric acid and coronary heart disease in 9,458 incident cases and 155,084 controls: Prospective study and meta-analysis. *PLoS Med* 2005;2:e76.
- 31 Solak Y, Akilli H, Atalay H, Kayrak M, Gok H, Turk S. The association of glomerular filtration rate and erectile dysfunction with severity of coronary artery disease in patients presenting with chest pain. *Int Urol Nephrol* 2010;42:765–71.
- 32 Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. *Int J Impot Res* 1999;11:319–26.
- 33 Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. *Hypertension* 2003;42:1206–52.
- 34 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539–53.
- 35 Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. *Ann Intern Med* 1999;130:461–70.
- 36 Johnson RJ, Tuttle KR. Much ado about nothing, or much to do about something? The continuing controversy over the role of uric acid in cardiovascular disease. *Hypertension* 2000;35:E10.
- 37 Johnson RJ, Kang DH, Feig D, et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? *Hypertension* 2003;41:1183–90.
- 38 Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. *N Engl J Med* 2008;359:1811–21.
- 39 de A Coutinho T, Turner ST, Kullo IJ. Serum uric acid is associated with microvascular function in hypertensive individuals. *J Hum Hypertens* 2007;21:610–5.
- 40 Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: A hypothesis. *Proc Natl Acad Sci U S A* 1981;78:6858–62.
- 41 Yu MA, Sanchez-Lozada LG, Johnson RJ, Kang DH. Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction. *J Hypertens* 2010;28:1234–42.
- 42 Chao HH, Liu JC, Lin JW, Chen CH, Wu CH, Cheng TH. Uric acid stimulates endothelin-1 gene expression associated with NADPH oxidase in human aortic smooth muscle cells. *Acta Pharmacol Sin* 2008;29:1301–12.
- 43 Maxwell AJ, Bruinsma KA. Uric acid is closely linked to vascular nitric oxide activity. Evidence for mechanism of association with cardiovascular disease. *J Am Coll Cardiol* 2001;38:1850–8.
- 44 Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. *Kidney Int* 2005;67:1739–42.
- 45 Butler R, Morris AD, Belch JJ, Hill A, Struthers AD. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. *Hypertension* 2000;35:746–51.
- 46 Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. *Circulation* 2002;106:221–6.
- 47 Kanbay M, Huddam B, Azak A, et al. A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. *Clin J Am Soc Nephrol* 2011;6:1887–94.
- 48 Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. *Circulation* 2003;107:416–21.

- 49 Lyngdoh T, Marques-Vidal P, Paccaud F, et al. Elevated serum uric acid is associated with high circulating inflammatory cytokines in the population-based ColaUS study. *PLoS ONE* 2011;6:e19901.
- 50 Kanellis J, Watanabe S, Li JH, et al. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. *Hypertension* 2003;41:1287–93.
- 51 Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. *Clin J Am Soc Nephrol* 2010;5:1388–93.
- 52 Kanbay M, Sanchez-Lozada LG, Franco M, et al. Microvascular disease and its role in the brain and cardiovascular system: A potential role for uric acid as a cardiorenal toxin. *Nephrol Dial Transplant* 2011;26:430–7.
- 53 Kodama S, Saito K, Yachi Y, et al. Association between serum uric acid and development of type 2 diabetes. *Diabetes Care* 2009;32:1737–42.
- 54 Sanchez-Lozada LG, Tapia E, Lopez-Molina R, et al. Effects of acute and chronic L-arginine treatment in experimental hyperuricemia. *Am J Physiol Renal Physiol* 2007;292:F1238–44.
- 55 Sanchez-Lozada LG, Tapia E, Avila-Casado C, et al. Mild hyperuricemia induces glomerular hypertension in normal rats. *Am J Physiol Renal Physiol* 2002;283:F1105–10.
- 56 Baldwin W, McRae S, Marek G, et al. Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome. *Diabetes* 2011;60:1258–69.
- 57 Nakagawa T, Hu H, Zharikov S, et al. A causal role for uric acid in fructose-induced metabolic syndrome. *Am J Physiol Renal Physiol* 2006;290:F625–31.
- 58 La Favor JD, Anderson EJ, Hickner RC, Wingard CJ. Erectile dysfunction precedes coronary artery endothelial dysfunction in rats fed a high-fat, high-sucrose, Western pattern diet. *J Sex Med* 2013;10:694–703.
- 59 Kang DH, Nakagawa T, Feng L, et al. A role for uric acid in the progression of renal disease. *J Am Soc Nephrol* 2002;13:2888–97.
- 60 Feig DI. Uric acid: A novel mediator and marker of risk in chronic kidney disease? *Curr Opin Nephrol Hypertens* 2009;18:526–30.
- 61 Kanbay M, Ozkara A, Selcoki Y, et al. Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions. *Int Urol Nephrol* 2007;39:1227–33.
- 62 Ogino K, Kato M, Furuse Y, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: A double-blind placebo-controlled crossover preliminary study. *Circ Heart Fail* 2010;3:73–81.
- 63 Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. *Am J Kidney Dis* 2006;47:51–9.